Introduction Patients with severe burns represent a challenge for the need of an early debridement before developing a progressive multiple organ dysfunction syndrome. The current standard of care (SOC) is surgical or non-surgical debridement, depending on the burn depth at the initial diagnosis. Surgical excision often sacrifices viable skin together with necrotic tissue and, in addition, results in significant blood and heat loss. Rapid and selective bromelain-based enzymatic debridement (NexobridTM) has the potential to offer an alternative method of eschar removal with fewer complications. Materials and methods In this study 60 patients affected by intermediate-deep burns, with a mean age of 48,5±23,6 and a mean TBSA of 31,00±15,66% were assessed. Half were treated with NexobridTM, the other half with the SOC. A series of parameters were evaluated: hospital stay, number of surgical interventions, variations in biochemical parameters (Hb, WBCs, PCR, fibrinogen), blood transfusion. Results A decrease in hospital stay, surgical interventions and reduction of blood transfusions were recorded. PCR value drop in few days were observed while WBCs and fibrinogen values did not show significant differences in the two groups. Survival rate were increased in the group of patients treated with NexobridTM. Conclusions NexobridTM is a rapid and selective eschar-removal product, which significantly reduces the number of surgical interventions and post-surgical complications, as well as the severity and the onset of septic complications.
No datasets are available for this submission.
No license information is available for this submission.